1873 Stock Overview
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Viva Biotech Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.91 |
| 52 Week High | HK$1.27 |
| 52 Week Low | HK$0.41 |
| Beta | 1.19 |
| 11 Month Change | 2.25% |
| 3 Month Change | 78.43% |
| 1 Year Change | -26.02% |
| 33 Year Change | -81.28% |
| 5 Year Change | -80.13% |
| Change since IPO | -79.41% |
Recent News & Updates
Recent updates
Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth
Oct 14
Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel
Aug 30Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely
Jun 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 14Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely
May 03A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Apr 26Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump
Jan 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 01These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way
Sep 25Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?
Jul 11These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively
Apr 14Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?
Dec 23Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?
Nov 06Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Jun 13We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt
Apr 17Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain
Mar 13Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares
Feb 06What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?
Jan 02Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?
Nov 21
Shareholder Returns
| 1873 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -1.1% | -11.0% | -2.7% |
| 1Y | -26.0% | -59.7% | 10.9% |
Return vs Industry: 1873 exceeded the Hong Kong Life Sciences industry which returned -59.7% over the past year.
Return vs Market: 1873 underperformed the Hong Kong Market which returned 10.9% over the past year.
Price Volatility
| 1873 volatility | |
|---|---|
| 1873 Average Weekly Movement | 12.8% |
| Life Sciences Industry Average Movement | 14.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1873 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1873's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,043 | Chen Cheney Mao | www.vivabiotech.com.cn |
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies.
Viva Biotech Holdings Fundamentals Summary
| 1873 fundamental statistics | |
|---|---|
| Market cap | HK$1.93b |
| Earnings (TTM) | -HK$341.91k |
| Revenue (TTM) | HK$2.15b |
0.9x
P/S Ratio-5,647x
P/E RatioIs 1873 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1873 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.00b |
| Cost of Revenue | CN¥1.32b |
| Gross Profit | CN¥671.61m |
| Other Expenses | CN¥671.93m |
| Earnings | -CN¥318.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00015 |
| Gross Margin | 33.66% |
| Net Profit Margin | -0.016% |
| Debt/Equity Ratio | 39.8% |
How did 1873 perform over the long term?
See historical performance and comparison